Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$49.38 - $63.75 $1.68 Million - $2.16 Million
-33,923 Reduced 50.29%
33,529 $2.09 Million
Q3 2023

Nov 13, 2023

SELL
$48.64 - $62.51 $705,474 - $906,645
-14,504 Reduced 17.7%
67,452 $3.79 Million
Q2 2023

Aug 10, 2023

BUY
$47.99 - $60.21 $916,656 - $1.15 Million
19,101 Added 30.39%
81,956 $4.14 Million
Q1 2023

May 09, 2023

BUY
$52.6 - $67.34 $96,731 - $123,838
1,839 Added 3.01%
62,855 $3.43 Million
Q4 2022

Feb 10, 2023

BUY
$59.56 - $76.6 $1.52 Million - $1.96 Million
25,596 Added 72.26%
61,016 $3.82 Million
Q3 2022

Nov 10, 2022

BUY
$57.96 - $78.12 $1.56 Million - $2.1 Million
26,859 Added 313.74%
35,420 $2.5 Million
Q2 2022

Aug 05, 2022

BUY
$39.5 - $64.42 $338,159 - $551,499
8,561 New
8,561 $485,000

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.49B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.